AMO: Ex-AMO chief Mazzo must face third insider trading trial

Former Advanced Medical Optics CEO James Mazzo must face a third trial on insider trading charges related to AMO's $2.8 billion acquisition by Abbott (NYSE:ABT) in 2009, after two previous trials ended in hung juries. Federal prosecutors in 2014 accused Mazzo of tipping a close friend and neighbor, former Orioles player Doug DeCinces, about the then-pending merger (Abbott subsequently sold the business to Johnson & Johnson (NYSE:JNJ) [...]The post Ex-AMO chief Mazzo must face third insider trading trial appeared first on MassDevice.